Anthem Biosciences Ltd. Stock Analysis ANTHEM.NS

Anthem BioSciences Ltd. engages in contract research, development and manufacturing, and organization with fully integrated operations spanning across drug discovery, development and manufacturing. The company is headquartered in Bangalore, Karnataka and currently employs 2,062 full-time employees. The company went IPO on 2025-07-21. The Company’s segments include CRDMO and Speciality Ingredients. The firm helps new and established biotech’s and big pharma, develop, optimize and test proteins, monoclonal antibodies, peptides, large molecules, small molecules, toxins and others. In addition to product research and development, it helps test drugs for safety, efficacy (in vitro and in vivo), pre-clinical animal studies in a GLP facility, clone development, antibody drug conjugates, research and development and manufacture of highly potent compounds, flow chemistry-based production and large-scale commercial product manufacture. Its CRDMO Services include Large Molecules, Small Molecules, HPAPI, Peptides, Lipids, ADCs and Oligonucleotides.